{"resourceType":"MedicationStatement","id":"mii-exa-medikation-medication-statement-caelyx","meta":{"profile":["https://www.medizininformatik-initiative.de/fhir/core/modul-medikation/StructureDefinition/MedicationStatement"],"security":[{"system":"http://terminology.hl7.org/CodeSystem/v3-ActReason","code":"HTEST","display":"test health data"}]},"status":"active","medicationReference":{"reference":"Medication/mii-exa-medikation-medication-caelyx"},"subject":{"reference":"Patient/example"},"effectiveDateTime":"2020-01-02T09:30:00+01:00","dosage":[{"text":"Doxorubicin (Caelyx) 50 mg je Quadratmeter Koerperoberflaeche alle vier Wochen per intravenoeser Tropfinfusion","timing":{"repeat":{"frequency":1,"period":4,"periodUnit":"wk"}},"route":{"coding":[{"system":"http://standardterms.edqm.eu","code":"20045000","display":"Intravenous use"}]}}]}